Management of vitiligo

Vitiligo can begin at any age, but starts before the age of 20 years in 50% of cases. It is usually slowly progressive, but intervals of months or years may elapse when the disease is static. At other times, vitiligo may progress rapidly. Most adult cases show a symmetrical pattern but segmental involvement can be seen, especially when vitiligo starts in childhood. A history of precipitation of the disease by severe sunburn or stress is found in 20% of cases. Vitiligo is often first noticed as pale macules on sunexposed sites of the face or dorsal aspects of the hands. The distribution is usually symmetrical (Fig. 1), and may show a periorificial pattern. Another pattern is unilateral or segmental vitiligo, sometimes in a dermatomal distribution (Fig. 2). Patients with an early age of onset have less likelihood of associated autoimmune disease of other organs. Pigment loss may be partial, complete or mixed in the same areas, so-called trichrome vitiligo. Hairs within patches of vitiligo often remain pigmented, but in older lesions the hairs also become amelanotic. Some patients with vitiligo also have halo naevi (Fig. 3). From 10 to 20% of patients experience some spontaneous repigmentation, usually in sun-exposed areas, or in a perifollicular distribution. Trauma to the skin can also result in further depigmentation, i.e. the Koebner phenomenon. Occupational vitiligo can occur too after contact with industrial chemicals such as substituted phenols. Sometimes it is confined to the areas of exposure, but is frequently more extensive, implying systemic exposure. Occupational vitiligo can be indistinguishable from the idiopathic variety.

[1]  P. Bossuyt,et al.  The development of guidelines for the treatment of vitiligo. Clinical Epidemiology Unit of the Istituto Dermopatico dell'Immacolata-Istituto di Recovero e Cura a Carattere Scientifico (IDI-IRCCS) and the Archives of Dermatology. , 1999, Archives of dermatology.

[2]  D. Gawkrodger,et al.  Identification of epitopes on tyrosinase which are recognized by autoantibodies from patients with vitiligo. , 1999, The Journal of investigative dermatology.

[3]  Legg,et al.  Impact of life events on the onset of vitiligo in adults: preliminary evidence for a psychological dimension in aetiology , 1998, Clinical and experimental dermatology.

[4]  D. Parsad,et al.  Combination of PUVAsol and Topical Calcipotriol in Vitiligo , 1998, Dermatology.

[5]  W. Westerhof,et al.  Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A. , 1997, Archives of dermatology.

[6]  A. Komiyama,et al.  Frequency and clinical correlates of vitiligo in myasthenia gravis , 1997, Journal of Neurology.

[7]  W. Westerhof,et al.  Laser treatment for further depigmentation in vitiligo , 1997, International journal of dermatology.

[8]  W. Westerhof,et al.  Repigmentation in vitiligo vulgaris by autologous minigrafting: results in nineteen patients. , 1995, Journal of the American Academy of Dermatology.

[9]  A. Alzate,et al.  An epidemiologic case-control study in a population with vitiligo. , 1995, Journal of the American Academy of Dermatology.

[10]  J. Wood,et al.  Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case study on 33 patients. , 1995, Dermatology.

[11]  D. Gawkrodger,et al.  Neuropeptide and neuronal marker studies in vitiligo , 1994, The British journal of dermatology.

[12]  A. M. Kahn,et al.  Vitiligo: treatment by dermabrasion and epithelial sheet grafting--a preliminary report. , 1993, Journal of the American Academy of Dermatology.

[13]  C. Zachariae,et al.  Autotransplantation in vitiligo: treatment with epidermal grafts and cultured melanocytes. , 1993, Acta dermato-venereologica.

[14]  L. Perfetti,et al.  Photochemotherapy with topical khellin and sunlight in vitiligo. , 1992, Dermatology.

[15]  M. Cork,et al.  Ocupational vitiligo and contact sensitivity to para‐tertiary butyl catechol , 1991, Contact dermatitis.

[16]  A. Wiskemann,et al.  [Phototherapy with UV-B in vitiligo]. , 1990, Zeitschrift fur Hautkrankheiten.

[17]  R. Halaban,et al.  Transplantation of human melanocytes. , 1987, The Journal of investigative dermatology.

[18]  J. Nordlund Vitiligo and Other Hypomelanosis of Hair and Skin , 1985 .

[19]  D. Rao,et al.  Studies on vitiligo I. Epidemiological profile in Calcutta, India , 1985, Genetic epidemiology.

[20]  G. Naughton,et al.  Antibodies to normal human melanocytes in vitiligo , 1983, The Journal of experimental medicine.

[21]  J. Nordlund,et al.  Extracellular granular material and degeneration of keratinocytes in the normally pigmented epidermis of patients with vitiligo. , 1982, The Journal of investigative dermatology.

[22]  J. Nordlund,et al.  Vitiligo: It Is Important , 1982 .

[23]  J. Nordlund,et al.  Vitiligo. It is important. , 1978, Archives of dermatology.

[24]  R. Winter,et al.  Vitiligo and juvenile diabetes mellitus. , 1977, Archives of dermatology.

[25]  K. Thomsen,et al.  Prevalence of vitiligo. Epidemiological survey on the Isle of Bornholm, Denmark. , 1977, Archives of dermatology.

[26]  J. Parrish,et al.  Photochemotherapy of vitiligo. Use of orally administered psoralens and a high-intensity long-wave ultraviolet light system. , 1976, Archives of dermatology.

[27]  A. Lerner On the etiology of vitiligo and gray hair. , 1971, The American journal of medicine.

[28]  C. J. Stevenson,et al.  VITILIGO, THYROID DISEASE AND AUTOIMMUNITY , 1968, The British journal of dermatology.

[29]  D. Dunlop EIGHTY-SIX CASES OF ADDISON'S DISEASE. , 1963, British medical journal.

[30]  A. Lerner Part V: Clinical Applications of Psoralens, and Related Materials: Vitiligo11From the Section of Dermatology, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut. , 1959 .